TY - JOUR
T1 - Staging Systems and Prognostic Factors as a Guide to Therapeutic Decisions in Multiple Myeloma
AU - Kyrtsonis, MC
AU - Maltezas, D
AU - Tzenou, T
AU - Koulieris, E
AU - Bradwell, Arthur
PY - 2009/4/1
Y1 - 2009/4/1
N2 - Multiple myeloma (MM) patients have a highly variable disease course and survival varies from a few months to more than 10 years. Numerous prognostic factors have been identified, including age, performance status (PS), serum albumin, beta(2)-microglobulin (beta M-2), lactate dehydrogenase (LDH), renal function, genetic factors, and serum free light chains (sFLCs) or their ratio (sFLCR). Several models have been built to separate patients into various risk groups with different outcomes. Staging systems need to be simple, accurate, and readily available in order to effectively guide treatment decisions now that effective treatments exist that prolong survival. The International Staging System (ISS) is currently in use; it is highly prognostic but presents some limitations. We suggest that the ISS prognostic potential could be improved with the addition of sFLCR and eventually LDH. Semin Hematol 46:110-117. (C) 2009 Published by Elsevier Inc.
AB - Multiple myeloma (MM) patients have a highly variable disease course and survival varies from a few months to more than 10 years. Numerous prognostic factors have been identified, including age, performance status (PS), serum albumin, beta(2)-microglobulin (beta M-2), lactate dehydrogenase (LDH), renal function, genetic factors, and serum free light chains (sFLCs) or their ratio (sFLCR). Several models have been built to separate patients into various risk groups with different outcomes. Staging systems need to be simple, accurate, and readily available in order to effectively guide treatment decisions now that effective treatments exist that prolong survival. The International Staging System (ISS) is currently in use; it is highly prognostic but presents some limitations. We suggest that the ISS prognostic potential could be improved with the addition of sFLCR and eventually LDH. Semin Hematol 46:110-117. (C) 2009 Published by Elsevier Inc.
U2 - 10.1053/j.seminhematol.2009.02.004
DO - 10.1053/j.seminhematol.2009.02.004
M3 - Article
C2 - 19389494
VL - 46
SP - 110
EP - 117
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 2
ER -